MM has received speaker or advisory board fees from AstraZeneca, Bayer, Boston Scientific, Boehringer-Ingelheim, Bristol-Myers Squibb, and Novo Nordisk. Patient consent for publication Not required.

New Delhi: AstraZeneca has got approval from the Subject Expert Committee ... ABYSS Trial Finds Elevated BP, HR & Deleterious CV Outcomes After Beta blocker Withdrawal Post-MI: ...

Aims There is a paucity of evidence supporting routine beta blocker (BB) use in patients undergoing percutaneous ... Funding The Melbourne Interventional Group is supported by Abbott, AstraZeneca, ...

AstraZeneca has appointed WPP as one of its primary oncology network partners. Under WPP’s new remit as a global creative partner, the agency will support U.S. and global advertising for AstraZeneca’s ...

An AstraZeneca spokesperson said ... and given anti-inflammatories and beta blockers, to slow down the heart rate and lower blood pressure. Three years on, Tyler, who works in a managerial ...

AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand. The vaccine — called Vaxzevria and ...

Beta-blockers were not associated with any excess ... Steg disclosed consulting to Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, Novo Nordisk, PhaseBio ...

AstraZeneca is adding to the explosion of interest in radiopharmaceuticals, inking a $2 billion buyout to meld Fusion Pharmaceuticals with its cancer unit. Fusion’s pipeline is led by a PSMA ...